Research Peptide

Semaglutide Reviews, Clinical Data, and Benefits

Blood Sugar Regulation
Weight Management
Cardiovascular Benefits
Metabolic Health
Potential for Non-Alcoholic Fatty Liver Disease
Neurological Benefits
Long-Term Sustainability
Anti-Obesity Use
Improvements in Quality of Life

Peptide

Semaglutide

Semaglutide is an FDA-approved treatment for diabetes and obesity. Discover its clinical benefits, mechanisms, and trial data, highlighting its impact on weight management and groundbreaking potential in metabolic health research.

How it Works

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), designed to replicate the function of this natural incretin hormone. Its enhanced structure resists degradation by dipeptidyl peptidase-IV, allowing it to remain active longer. By promoting insulin release and reducing glucagon levels based on blood glucose concentration, semaglutide effectively controls both fasting and postprandial glucose levels.

Primary Research

Alternative Names

Ozempic, Rybelsus, Wegovy, A10BJ06

Key Studies

Semaglutide for the Treatment of Overweight and Obesity: a Review

The Discovery and Development of Liraglutide and Semaglutide

Effects of Semaglutide on Risk of Cardiovascular Events Across a Continuum of Cardiovascular Risk: Combined Post Hoc Analysis of the SUSTAIN and PIONEER Trials

Potential Risks

Gastrointestinal issues such as nausea, diarrhea, and abdominal discomfort
Increased risk of pancreatitis, with symptoms including severe abdominal pain
Concerns over thyroid C-cell hyperplasia and cancer, primarily observed in animal studies
Not suitable for individuals with a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Limited approval for use only in type 2 diabetes and obese patients, with caution advised in other populations

Chemical Structure

What is Semaglutide?

SEMAGLUTIDE is a medication gaining global attention for its impressive efficacy in treating type 2 diabetes (T2D) and promoting weight loss. Developed as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), it mimics the action of a natural hormone in the body to regulate blood sugar levels. Its formulation, available as an injection or oral tablet, offers patients versatile treatment options.

First approved by the FDA for managing T2D, semaglutide’s scope has since expanded to address obesity and even cardiovascular risks. By helping individuals improve their glycemic control and shed excess weight, SEMAGLUTIDE provides a dual benefit often sought in modern medical treatments.

As we delve deeper into semaglutide’s mechanisms, benefits, and safety, it becomes evident why this peptide has become a breakthrough in medical science. Let us explore how SEMAGLUTIDE works, its advantages, and its role in modern therapy.

How Does Semaglutide Work?

SEMAGLUTIDE works by activating specific receptors in the body to improve metabolic processes, regulate blood sugar levels, and reduce appetite.

Mechanism of Action

SEMAGLUTIDE is a GLP-1 receptor agonist, meaning it binds to receptors found in the pancreas, brain, and gut. This interaction triggers a cascade of effects crucial for managing blood glucose levels and appetite. In the pancreas, SEMAGLUTIDE stimulates insulin secretion when blood sugar levels are high, helping the body absorb glucose efficiently. At the same time, it suppresses glucagon, a hormone responsible for raising blood sugar levels, ensuring a balanced metabolic state.

Moreover, semaglutide slows gastric emptying, meaning food stays in the stomach longer. This delay moderates post-meal blood sugar spikes and creates a sensation of fullness, reducing overall calorie intake. Additionally, its effects on brain receptors reinforce healthy eating habits by reducing cravings and promoting satiety. Such combined actions make SEMAGLUTIDE highly effective for both diabetes control and weight loss.

Impact on Blood Sugar and Insulin Sensitivity

One of semaglutide’s primary roles is its profound effect on blood sugar regulation. By enhancing insulin secretion and reducing glucagon levels, it ensures blood glucose remains within a healthy range after meals. This dual action significantly improves insulin sensitivity over time, a critical factor for individuals with type 2 diabetes.

Key benefits include:

Post-meal glucose control: Limits dangerous blood sugar spikes, especially after high-carbohydrate meals.
Improved fasting glucose levels: Helps reduce long-term risks of complications like neuropathy and retinopathy.
Consistent glucose regulation: Lowers the likelihood of severe hypoglycemia, offering patients more stable day-to-day energy levels.
Improved HbA1c levels: Demonstrated to reduce average blood sugar levels over three months.

Through these mechanisms, SEMAGLUTIDE not only improves immediate glycemic outcomes but also addresses the root causes of insulin resistance for lasting health improvements.

Role in Weight Management

Semaglutide’s role in weight management is transformative, particularly for individuals struggling with obesity. By acting on the brain’s appetite-control centers, it helps reduce hunger and cravings, leading to lower caloric intake. Patients often report feeling satisfied with smaller meals, a critical factor for sustainable weight loss.

Its benefits for weight management extend beyond appetite suppression and include:

Reduced fat mass: SEMAGLUTIDE encourages the breakdown of stored fat, leading to measurable reductions in body fat percentage over time.
Improved metabolic health: By lowering visceral fat and waist circumference, it decreases risks associated with heart disease and metabolic syndrome.
Enhanced physical activity levels: Many patients find that weight loss improves their mobility and energy, motivating further engagement in exercise routines.
Psychological benefits: Achieving weight loss goals often boosts confidence and mental well-being, contributing to improved adherence to healthier lifestyles.
Lowered inflammation: Reducing excess fat can lead to decreased levels of chronic inflammation, a key factor in numerous health conditions.

Clinical trials have shown that patients using SEMAGLUTIDE for weight loss achieved reductions of up to 15% of their body weight compared to those on placebo. This efficacy has positioned SEMAGLUTIDE as an innovative solution not only for diabetes management but also for combating obesity in non-diabetic populations.

Where to Buy

There are a lot of shady peptide sites out there — underdosed, untested, and unreliable. BioEdge Labs is different. Every product is fully third-party tested. If you care about your research, this is the lab to trust.

Visit BioEdge Labs

The Benefits of Semaglutide

SEMAGLUTIDE has emerged as a breakthrough treatment, offering diverse benefits for managing type 2 diabetes (T2D) and obesity. Beyond these primary uses, its potential in other therapeutic areas continues to expand. This versatility has made it a cornerstone of modern medical innovation.

Its mechanisms allow it to address not just symptoms but also underlying causes of chronic health issues.

Let’s examine the key benefits in detail.

Treatment for Type 2 Diabetes (T2D)

Managing type 2 diabetes requires consistent blood sugar regulation to prevent long-term complications. Semaglutide’s dual action, stimulating insulin and suppressing glucagon, helps patients achieve better glycemic control while improving overall metabolic health.

Improved HbA1c levels: Clinical trials reveal that semaglutide lowers HbA1c levels significantly within the first 12 weeks. This improvement directly reduces risks of diabetes-related complications like neuropathy and kidney damage.
Post-meal glucose control: By smoothing spikes in blood sugar after meals, it helps patients maintain stable energy levels throughout the day. Such stability can significantly enhance day-to-day well-being.
Ease of use: A once-weekly injection schedule simplifies treatment, especially for patients who struggle with daily medications.

For many patients, these benefits translate to improved quality of life and fewer diabetes-related health scares.

Lowering Cardiovascular Risks

Cardiovascular health is a top concern for individuals with T2D or obesity. SEMAGLUTIDE addresses multiple cardiovascular risk factors, making it an essential medication for high-risk patients.

Lowers LDL cholesterol: By reducing harmful cholesterol levels, SEMAGLUTIDE slows plaque buildup in arteries. This directly reduces the chances of developing conditions like atherosclerosis.
Reduces blood pressure: Improved vascular health alleviates strain on the heart, decreasing the risk of heart disease. The combination of weight loss and better metabolic control further enhances this benefit.
Supports weight loss: Excess body weight is a major contributor to cardiovascular strain. SEMAGLUTIDE not only promotes weight loss but also improves fat distribution, lowering the risk of cardiac complications.

These cardiovascular benefits make SEMAGLUTIDE a valuable tool for long-term health management, particularly for patients prone to heart disease or stroke.

Weight Loss Advantages

Semaglutide’s role in weight management goes beyond appetite suppression. By influencing multiple physiological pathways, it promotes sustainable and measurable weight loss, even in individuals without diabetes.

Patients using SEMAGLUTIDE report:

Sustained weight loss: Clinical trials show reductions of up to 15% of body weight in some users. Many patients maintain these results even after discontinuing treatment, highlighting its long-term efficacy.
Reduced visceral fat: It targets harmful fat deposits around internal organs, improving metabolic health and lowering risks of chronic diseases. This makes it especially effective in tackling obesity-related complications.
Increased energy and mobility: Weight reduction often results in improved physical function. Patients report feeling more active and capable of engaging in exercise routines, creating a positive feedback loop.
Psychological improvements: Many users experience boosted self-esteem after achieving significant weight loss goals. These mental health benefits often reinforce adherence to healthier lifestyle choices.

Other Emerging Benefits

Semaglutide’s potential extends beyond diabetes and weight management, with research uncovering its versatility in addressing a range of conditions.

Kidney protection: Initial findings suggest it slows the progression of diabetic nephropathy. This could reduce the need for dialysis in advanced cases, a life-changing benefit for many.
Liver health: SEMAGLUTIDE shows promise in reducing liver fat, offering hope for individuals with non-alcoholic fatty liver disease (NAFLD). This benefit is particularly important as NAFLD often coexists with diabetes and obesity.
Cognitive function: Early studies indicate a potential role in reducing cognitive decline in patients with metabolic disorders. Researchers believe its effects on inflammation and blood flow may contribute to this benefit.
Systemic anti-inflammatory effects: By reducing chronic inflammation, SEMAGLUTIDE may offer relief for conditions like arthritis. These anti-inflammatory properties are being explored for broader health applications.

The growing list of benefits highlights semaglutide’s potential to address multiple conditions simultaneously, making it an invaluable medication for both patients and researchers.

Semaglutide for Weight Loss in Non-Diabetics

SEMAGLUTIDE has demonstrated remarkable results in weight management, extending its benefits to non-diabetic individuals struggling with obesity. Approved for chronic weight management, it is an effective alternative to invasive procedures like bariatric surgery, providing patients with an opportunity for sustainable weight loss through non-surgical means.

Its effectiveness lies in its ability to suppress appetite and regulate metabolic processes. By acting on the brain’s appetite-control centers, SEMAGLUTIDE reduces hunger, increases feelings of satiety, and lowers caloric intake. Additionally, it slows gastric emptying, ensuring that food remains in the stomach longer, which further aids in controlling appetite.

Clinical trials, including the STEP program, have shown that SEMAGLUTIDE promotes significant weight reductions of up to 15% of total body weight over 20 weeks. This weight loss is accompanied by improved metabolic markers, such as reduced waist circumference and decreased visceral fat.

Moreover, semaglutide’s weight-loss benefits extend beyond physical changes. Many patients report increased energy levels, improved mobility, and enhanced mental well-being. These factors contribute to better adherence to healthier lifestyle habits, creating a positive feedback loop for long-term success. With its proven efficacy and safety profile, SEMAGLUTIDE represents a groundbreaking solution for non-diabetic individuals aiming to overcome obesity.

Side Effects and Safety Considerations

While SEMAGLUTIDE is highly effective, like any medication, it comes with potential side effects and safety considerations. Understanding these is critical for ensuring proper use and minimizing risks.

Commonly Reported Side Effects

Semaglutide’s common side effects are mostly mild and transient, typically subsiding as patients adjust to treatment. They include:

Rare but Serious Adverse Effects

Although rare, some serious side effects associated with SEMAGLUTIDE use require attention. These adverse effects highlight the importance of medical supervision during treatment.

Hypoglycemia: While uncommon, hypoglycemia can occur when SEMAGLUTIDE is used alongside other diabetes medications, such as insulin. Symptoms may include dizziness, sweating, confusion, and severe fatigue. Monitoring blood sugar levels during treatment is essential to avoid this complication.
Thyroid cancer: Animal studies have linked SEMAGLUTIDE to thyroid C-cell hyperplasia and malignancies. Although this hasn’t been confirmed in humans, patients with a family history of thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should avoid using semaglutide.
Pancreatic inflammation and cancer: SEMAGLUTIDE may increase the risk of pancreatitis, presenting symptoms such as severe abdominal pain and vomiting. While the connection to pancreatic cancer is not definitively established, patients with a history of pancreatitis are advised to proceed with caution.
Kidney injury: Dehydration caused by gastrointestinal upset, such as persistent vomiting or diarrhea, can lead to acute kidney injury. This risk underscores the importance of hydration and prompt medical attention if symptoms persist.
Gallbladder disease: Research has linked SEMAGLUTIDE use to an increased risk of gallbladder issues, such as gallstones and cholecystitis. Symptoms include upper abdominal pain, jaundice, and fever, which may require medical intervention.
Diabetic retinopathy: Rare cases of worsening diabetic retinopathy have been reported, particularly in patients with preexisting eye conditions. This underscores the need for regular eye examinations during treatment.
Hypersensitivity reactions: Severe allergic reactions, including anaphylaxis and angioedema, though rare, are possible. These require immediate discontinuation of the medication and urgent medical care.

General Safety Profile

SEMAGLUTIDE is considered safe when used as prescribed, with most side effects being mild and self-limiting. Its weekly dosing schedule reduces the likelihood of severe adverse reactions compared to other treatments. Furthermore, clinical trials consistently demonstrate that its benefits outweigh its risks in approved populations.

That said, safety depends on proper administration and adherence to guidelines. Healthcare providers should assess each patient’s individual risk factors, including preexisting conditions, before initiating therapy. Proper monitoring during treatment can help mitigate potential risks and ensure the best possible outcomes for patients.

Precautions and Warnings

Despite its favorable safety profile, SEMAGLUTIDE is not recommended for everyone. Patients must consult their healthcare providers to determine whether the medication is appropriate for their specific needs.

Pregnancy and lactation: SEMAGLUTIDE is not recommended for pregnant or breastfeeding women due to potential risks to the fetus or infant. Animal studies have shown developmental abnormalities, making this a significant precaution.
Pediatric use: While SEMAGLUTIDE is approved for children aged 12 and older with obesity, its safety in younger populations remains unestablished. Caution is advised in prescribing it to adolescents.
Geriatric patients: Older adults with certain conditions, such as kidney or liver impairment, may require adjusted dosages or closer monitoring to avoid complications.
Drug interactions: SEMAGLUTIDE may slow gastric emptying, potentially altering the absorption of oral medications. Patients should disclose all current medications to their healthcare provider to prevent harmful interactions.
Preexisting conditions: Individuals with a history of thyroid cancer, pancreatitis, or severe gastrointestinal disorders should discuss potential risks thoroughly with their doctor before starting semaglutide.

These precautions emphasize the importance of personalized medical advice. With proper guidance, patients can safely benefit from this innovative treatment while minimizing potential risks.

Where to Buy

Visit BioEdge Labs

Peptides can get expensive, but as an FYI – BioEdge is doing 15% off this month.

Use code report15 at bioedgepeptides.com

One of the few suppliers that consistently delivers what their lab reports claim.

Semaglutide Dosage and Administration

SEMAGLUTIDE is available in both subcutaneous and oral formulations, tailored for specific uses such as type 2 diabetes (T2D) management and weight loss. Its dosage and administration protocols are designed to optimize efficacy while minimizing adverse effects. Below are detailed guidelines for both forms of administration.

Recommended Dosage for T2D

Subcutaneous semaglutide, sold under the brand name Ozempic, is a cornerstone of T2D treatment due to its long-acting formulation. The dosing schedule ensures steady glucose control with minimal intervention.

Initial dose

0.25 MG Weekly

For the first 4 weeks to allow the body to adjust

Maintenance dose

0.5 MG weekly

Increased to 0.5 mg weekly for sustained glycemic control. If further reductions in blood sugar levels are required, the dosage can be escalated up to 2 mg per week.

Administration Tips

This structured dosing protocol helps patients achieve consistent glycemic outcomes while reducing risks associated with fluctuating blood sugar levels.

Timing: Injections should be given on the same day each week.
Missed doses: If a dose is missed, it can be administered within 5 days, followed by resumption of the regular schedule.

Dosage Guidelines for Weight Loss

When prescribed for chronic weight management, SEMAGLUTIDE is marketed as Wegovy. Its dosing schedule allows for gradual escalation to ensure tolerance while delivering substantial weight loss benefits.

Initial dose

0.25 MG Weekly

For the first 4 weeks

Weeks 5-8

0.5 MG weekly

Weeks 9-12

1 MG Weekly

Weeks 13-16

1.7 MG weekly

Maintenance dose

2.4 MG Weekly

From week 17 onward

Note

If patients cannot tolerate at least 1.7 mg weekly, discontinuation may be advised. Missed doses should be taken within 5 days, with subsequent doses continuing on the usual schedule. This gradual titration minimizes side effects such as nausea while maximizing adherence and outcomes.

Where to Buy

Visit BioEdge Labs

Administration of Semaglutide Oral Tablets

Rybelsus, the oral version of semaglutide, provides a non-injectable option for managing T2D. Though convenient, precise administration guidelines must be followed to ensure proper absorption.

Initial dose

3 MG Weekly

For the first 30 days

Adjustment

7 MG daily

After 30 days. If additional glycemic control is required, the dose can be escalated to 14 mg daily.

Administration Tips

Because there is no direct dose equivalency between oral and injectable forms, transitioning between these options requires careful planning. This oral formulation expands access to semaglutide, particularly for those who prefer non-invasive treatments.

Timing: Tablets must be swallowed whole with a small amount of water (no more than 4 ounces) at least 30 minutes before eating, drinking, or taking other medications. This ensures maximum absorption.

Missed doses: Should be skipped entirely without doubling up.

Comparing Semaglutide and Liraglutide

SEMAGLUTIDE and LIRAGLUTIDE are both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) widely used for type 2 diabetes and weight management. While they share similarities, their differences make each peptide unique in terms of effectiveness and convenience.

Differences in Mechanism of Action

Both SEMAGLUTIDE and LIRAGLUTIDE mimic the natural hormone GLP-1, which regulates blood sugar by increasing insulin secretion, suppressing glucagon, and slowing gastric emptying. These effects also contribute to appetite suppression and weight loss.

However, semaglutide’s albumin-binding ability gives it an extended half-life, allowing for weekly dosing compared to LIRAGLUTIDE daily injections. This makes SEMAGLUTIDE more convenient for patients who prefer fewer injections. Additionally, SEMAGLUTIDE is available in an oral tablet form, a significant advancement for those seeking alternatives to injections.

While LIRAGLUTIDE has slightly higher receptor affinity, semaglutide’s longer action ensures sustained therapeutic effects. These differences provide SEMAGLUTIDE with a notable edge, especially in terms of convenience and dosing efficiency.

Comparative Effects on Weight and Glucose Control

When it comes to blood sugar management, SEMAGLUTIDE outperforms LIRAGLUTIDE in clinical trials. It achieves greater reductions in fasting and postprandial glucose levels, alongside improved insulin sensitivity.

For weight loss, SEMAGLUTIDE is also superior. It exerts stronger effects on the hypothalamus, leading to enhanced satiety and a more substantial reduction in calorie intake. These metabolic benefits contribute to more significant and lasting weight reductions compared to liraglutide.

Despite semaglutide’s advantages, cost and patient-specific factors may influence the choice between these two peptides. Each has its strengths, but semaglutide’s extended duration and versatile options make it a more efficient choice for many users.

Where to Buy Semaglutide Online | 2026 Edition

SEMAGLUTIDE is an effective treatment for type 2 diabetes and chronic weight management, available in several formulations under different brand names. Its online availability has made it more accessible, although prices and formats may vary depending on the region.

Despite its higher cost compared to other GLP-1 receptor agonists, semaglutide’s long-term benefits justify the investment. Studies have consistently highlighted its superior performance over alternatives like dulaglutide, particularly in terms of cost-effectiveness and clinical results. Choosing a reputable vendor is essential to ensure product quality and safety.

Reputation

Look for reviews and testimonials from other buyers to assess the vendor’s reliability.

Testing and Transparency

Ensure the supplier provides certificates of analysis (COAs) from third-party laboratories to confirm product purity and authenticity.

Customer Support

A reliable vendor will have accessible support channels to address inquiries or concerns.

Recommended Vendor

BioEdge Research Labs

If you are seeking a trusted source for high-quality research peptides, BioEdge Research Labs is an excellent choice. Their commitment to product quality and customer satisfaction makes them a leader in the peptide industry.

Partnerships with Third-Party Labs: BioEdge Labs collaborates with independent laboratories to conduct rigorous testing on each product batch. This ensures their peptides meet stringent standards of quality, purity, and potency.
Flexible Reship and Return Policies: With an incredibly customer-friendly reship and return policy, BioEdge Labs prioritizes buyer satisfaction. They also offer optional shipping insurance for added peace of mind.
Commitment to Responsible Distribution: The company emphasizes safe and responsible peptide distribution, making it clear that their products are intended only for use by qualified researchers.
Excellent Reputation: Known for their credibility in the peptide community, BioEdge Labs boasts a low rate of credit card chargebacks and numerous positive online reviews.
Educational Resources: Their website provides valuable information on peptide science and terminology, helping buyers make informed decisions.

Bacteriostatic Water and Semaglutide

The preparation of SEMAGLUTIDE for research requires precise handling and appropriate tools to maintain its efficacy. Bacteriostatic water, along with sterile vials, is essential for safely reconstituting the peptide. These items play a crucial role in ensuring the peptide remains stable and uncontaminated during use.

Proper preparation also reduces the risk of errors that might compromise research outcomes. A well-equipped lab simplifies the process, allowing researchers to focus on achieving accurate and reliable results.

While sourcing these materials is necessary, careful consideration should be given to quality and compatibility with SEMAGLUTIDE to support successful research.

Frequently Asked Questions (FAQ)

Is Semaglutide a Steroid?

No, SEMAGLUTIDE is not a steroid. Unlike compounds that affect androgen receptors, SEMAGLUTIDE is a polypeptide consisting of 31 amino acids. It mimics the action of the incretin hormone GLP-1, which regulates blood sugar levels and appetite.

How is Semaglutide Delivered?

Once reconstituted, SEMAGLUTIDE is administered subcutaneously. This delivery method allows for steady absorption and ensures optimal effectiveness.

Does Semaglutide Build Muscle?

SEMAGLUTIDE has no anabolic properties and is not associated with muscle growth. Its primary effects are related to metabolic regulation and weight management.

Is Semaglutide Legal?

Yes, SEMAGLUTIDE is FDA-approved in the United States for treating type 2 diabetes and chronic weight management in specific populations. It is sold under brand names like Wegovy and Ozempic and requires a prescription for therapeutic use.

How to Take Semaglutide?

For research purposes, SEMAGLUTIDE is typically supplied as a lyophilized powder. This powder must be reconstituted into a liquid using a suitable solvent such as bacteriostatic water.

Does Semaglutide Increase Testosterone?

No, SEMAGLUTIDE does not impact testosterone levels. Its mechanisms are focused on blood sugar regulation and appetite suppression, with no effect on hormone production.

Semaglutide | Key Takeaways

SEMAGLUTIDE has redefined the treatment landscape for type 2 diabetes and obesity, offering unparalleled efficacy in blood sugar control and weight management. Its ability to address metabolic and cardiovascular risks highlights its versatility and impact.

From its mechanisms of action to its comparative benefits over LIRAGLUTIDE, SEMAGLUTIDE stands out as a cutting-edge therapy. Beyond diabetes and weight loss, emerging applications such as improving liver health and reducing systemic inflammation further solidify its place as one of the most promising peptides available today.

To explore Semaglutide other high purity peptides visit the BioEdge site to order directly.

References

Baby, M. T., & Sheets, F. (2021)

Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994–. Tofacitinib (Xeljanz®, Xeljanz XR®).

Cabral Lopes, A., Roque, F., Lourenço, O., Herdeiro, M. T., & Morgado, M. (2023)

Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert Opinion on Drug Safety, 22(6), 455-461.

de Paiva, I. H. R., da Silva, R. S., Mendonça, I. P., de Souza, J. R. B., & Peixoto, C. A. (2024)

Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. Journal of Neuroimmune Pharmacology, 19(1), 36.

Fatima, N., Anand, A., Palvia, A. R., Kaur, A., Azeez, G. A., Thirunagari, M., & Butt, S. R. R. (2024)

Efficacy of Different Doses and Forms of the GLP-1 Receptor Agonist Semaglutide in Weight Reduction Among Non-diabetic Obese or Overweight Populations. Cureus, 16(9), e68786.

Holst, J. J., & Madsbad, S. (2017)

Semaglutide seems to be more effective the other GLP-1Ras. Annals of translational medicine, 5(24).

Irfan, H. (2024)

Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial. Current Problems in Cardiology, 49(1), 102060.

Knudsen, L. B., & Lau, J. (2019)

The discovery and development of liraglutide and semaglutide. Frontiers in endocrinology, 10, 155.

Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022)

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 23(3), 521-539.

Mann, J. F., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., … & Perkovic, V. (2021)

Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes, Obesity and Metabolism, 23(9), 2058-2066.

Overgaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021)

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Reports Medicine, 2(9).

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … & STEP 4 Investigators. (2021)

Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama, 325(14), 1414-1425.

Smits, M. M., & Van Raalte, D. H. (2021)

Safety of semaglutide. Frontiers in endocrinology, 12, 645563.

Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., … & Horowtiz, M. (2023)

Weight loss with subcutaneous semaglutide versus other glucagon‐like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Internal medicine journal, 53(8), 1311-1320.

Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., … & Garvey, W. T. (2023)

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity, 31(3), 703-715.

Wu, W., Tong, H. M., Li, Y. S., & Cui, J. (2024)

The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis. Endocrine, 83(3), 571-584.

Joe Mars

Founder, The Peptide Report

I’m Joe Mars, and I’ve dedicated the past ten years to understanding peptide therapy, longevity, and how to optimize the body through practical, real-life testing. My journey started when I was tired, inflamed, and aging faster than I should have been. Clear information on peptides was almost impossible to find, so I dug in, researched nonstop, and tested protocols on myself.

Over the years, I have learned from experts like Jay Campbell, Dr. Seeds, Jim LaValle, and Ben Greenfield, and I have completely transformed my health. Now in my fifties, I feel stronger and sharper than I did in my twenties. That experience is why I write. I want to give people simple and honest guidance so they can use peptides safely and effectively.

I believe in data, smart protocols, and taking responsibility for your own health. You are the protocol. Your habits, your consistency, and your awareness shape your results. Through The Peptide Report, I share what actually works so you can make informed decisions and build a healthier, more resilient body.